Alivexis, Inc.
Revolutionizing small molecule drug discovery with a drug discovery approach that combines unique strengths
Alivexis is revolutionizing small molecule drug discovery with a combination of core biology insights, a cutting-edge drug discovery platform, and a unique drug discovery research pipeline. Molecules are designed in silico by modeling molecules from the crystal structure data of the target molecule, and the designed compounds are actually synthesized and screened. Hit compounds obtained by screening are further synthesized in silico to create lead compounds and ultimately to finalize candidate compounds. Rather than synthesize or assay in-house, we outsource everything. This method makes it possible to accelerate drug discovery until an IND (clinical trial) application can be submitted in about three years.
- Establishment Date
- August 2016
- Business
- Drug discovery using computational science
- CEO
- Shun Kimura, CEO, Kazuki Ohno, COO
KII’s Perspective
With members who have been involved in drug discovery research and business development on the front lines of pharmaceutical companies, Modulus Discovery has pipeline and business development capabilities that are on par with Western bio-ventures. We hope to continuously generate large-scale out-licensing to major European and American companies.
KII growth support
Support for collaboration with academia
